In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Monetary awards worth Rs 1.20 crore were presented amongst the winners for their remarkable contributions
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
The inspection concluded with no observation (FDA-483) issued.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Subscribe To Our Newsletter & Stay Updated
